HC Wainwright Has Lowered Expectations for PDS Biotechnology (NASDAQ:PDSB) Stock Price

PDS Biotechnology (NASDAQ:PDSB) had its target price decreased by research analysts at HC Wainwright from $21.00 to $13.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock.

PDS Biotechnology Trading Up 0.8 %

NASDAQ PDSB opened at $1.26 on Thursday. The stock has a market capitalization of $48.12 million, a price-to-earnings ratio of -1.09 and a beta of 1.68. PDS Biotechnology has a 52 week low of $1.13 and a 52 week high of $4.42. The stock’s 50 day moving average price is $1.40 and its two-hundred day moving average price is $2.16. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. As a group, analysts anticipate that PDS Biotechnology will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd increased its holdings in shares of PDS Biotechnology by 241.8% during the 3rd quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after acquiring an additional 47,528 shares during the last quarter. Geode Capital Management LLC lifted its position in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after acquiring an additional 37,142 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of PDS Biotechnology in the fourth quarter valued at approximately $26,000. Virtu Financial LLC acquired a new stake in PDS Biotechnology during the 4th quarter worth approximately $89,000. Finally, Blair William & Co. IL boosted its stake in PDS Biotechnology by 29.4% in the 4th quarter. Blair William & Co. IL now owns 157,500 shares of the company’s stock valued at $257,000 after purchasing an additional 35,757 shares during the period. 26.84% of the stock is owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.